A Phase I/II Clinical Trial of Lenalidomide in Combination With AT-101 for the Treatment of Relapsed B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

Sponsors

Lead sponsor: Mayo Clinic

Collaborator: National Cancer Institute (NCI)

Source Mayo Clinic
Brief Summary

This phase I/II trial studies the side effects and best dose of lenalidomide when given together with R-(-)-gossypol acetic acid and to see how well they work in treating patients with B-cell chronic lymphocytic leukemia (B-CLL) that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, may stimulate the immune system to attack cancer cells. R-(-)-gossypol acetic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and causing the cells to die. Giving lenalidomide with R-(-)-gossypol acetic acid may be an effective treatment for relapsed or refractory B-CLL. - Funding Source - FDA OOPD

Detailed Description

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) of lenalidomide in combination with AT-101 (R-(-)-gossypol acetic acid). (Phase I) II. To assess the overall response rate of lenalidomide in combination with AT-101. (Phase II)

SECONDARY OBJECTIVES:

I. To assess the overall response rates of lenalidomide in combination with AT-101 at 6 months and 12 months.

II. To evaluate time to progression (TTP) for the combination of lenalidomide + AT-101.

III. To evaluate the safety of this combination in patients with relapsed B-CLL.

TERTIARY OBJECTIVES:

I. To conduct correlative studies for further understanding of the mechanism of antitumor activity of lenalidomide and lenalidomide + AT-101.

OUTLINE: This is a phase I dose-escalation study of lenalidomide followed by a phase II study.

Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21. Beginning in course 3, patients also receive AT-101 PO twice daily (BID) on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 3 months for up to 2 years.

Overall Status Active, not recruiting
Start Date July 9, 2015
Completion Date June 1, 2020
Primary Completion Date December 14, 2018
Phase Phase 1/Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Maximum tolerated dose of lenalidomide when given in combination with AT-101, defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6 new patients) (Phase I) Up to day 28 of course 2
Overall response rate (complete response [CR], CR with incomplete marrow recovery, clinical CR, nodular partial response [PR], and PR) (Phase II) Up to 2 years
Secondary Outcome
Measure Time Frame
Incidence of adverse events, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies (Phase I) Up to 2 years
Incidence of toxicity, defined as adverse events classified as possibly, probably, or definitely related to study treatment, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies or ordinal Common Toxicity Criteria (Phase I) Up to 2 years
Overall response rate (Phase II) Up to 12 months
Time to progression (Phase II) The time from registration to the earliest date of documentation of disease progression, assessed up to 2 years
Incidence of adverse events, graded according to the Grading Scale for Hematologic Adverse Events in CLL Studies (Phase II) Up to 30 days after the last day of study treatment
Enrollment 5
Condition
Intervention

Intervention type: Drug

Intervention name: Lenalidomide

Description: Given PO

Arm group label: Treatment (lenalidomide in combination with AT-101)

Intervention type: Drug

Intervention name: R-(-)-Gossypol Acetic Acid

Description: Given PO

Arm group label: Treatment (lenalidomide in combination with AT-101)

Intervention type: Other

Intervention name: Laboratory Biomarker Analysis

Description: Correlative studies

Arm group label: Treatment (lenalidomide in combination with AT-101)

Eligibility

Criteria:

Inclusion Criteria:

- Understand and voluntarily sign an informed consent form

- Able to adhere to the study visit schedule and other protocol requirements

- Diagnosis of B-CLL, confirmed by flow cytometric analysis and as per the criteria outlined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL)/Hallek December 2008

- Any prior therapy for B-CLL must have been discontinued >= 28-days prior to registration

- Patients must have absolute lymphocyte counts (ALC) of more than 5,000 cell/mm^3

- During phase I: all patients with relapsed disease will be eligible if they have received at least 1 prior standard CLL therapy and no more than 4 prior therapies (one of which must be a purine analog and/or an alkylating agent)

- During phase II: all patients with relapsed disease will be eligible if they have received a minimum of 1 prior standard therapy and a maximum of 2 prior treatments (one of which must be a purine analog and/or an alkylating agent) for B-CLL and have developed relapse disease

- Note: patients who have refractory disease (defined as - progressive disease on last treatment, or less than 6 months of clinical response to the last treatment) will not be eligible

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 at registration

- Absolute neutrophil count >= 1500/mm^3

- Platelet count >= 30,000/mm^3

- Serum creatinine =< 1.5 x upper limit of normal (ULN)

- Total bilirubin =< 1.5 mg/dL or direct bilirubin =< 1.0 mg/dL for patients with Gilberts syndrome

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x ULN or =< 5 x ULN if hepatic disease is present

- Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL 10-14 days prior to and again within 24 hours before starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure

- A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)

- All study participants must be registered into the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist

- Patient must require treatment for symptomatic B-CLL as defined by the by the IWCLL/Hallek, December 2008 criterion or as determined clinically necessary by the treating physician

- Willing to provide blood and baseline bone marrow aspirate samples for correlative research purposes

Exclusion Criteria:

- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form

- Pregnant or lactating females

- Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study

- Use of any other experimental drug or therapy =< 28 days prior to registration

- Known hypersensitivity to thalidomide or lenalidomide

- The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs

- Patients with of history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix, unless in complete remission and off therapy for that disease for > 3 years)

- Patient with history of cardiac arrest within the past 6 months

- Patients with history of prior bowel resection, malabsorption syndrome, inflammatory bowel disease, prior bowel obstruction (partial or complete), Crohn disease, or any other disease significantly affecting the gastrointestinal tract

- Prior use of gossypol or AT-101

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Overall Official
Last Name Role Affiliation
Asher Chanan-Khan Principal Investigator Mayo Clinic
Location
facility
Mayo Clinic in Florida | Jacksonville, Florida, 32224-9980, United States
Roswell Park Cancer Institute | Buffalo, New York, 14263, United States
Location Countries

United States

Verification Date

December 2018

Responsible Party

Responsible party type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Arm group label: Treatment (lenalidomide in combination with AT-101)

Arm group type: Experimental

Description: Patients receive lenalidomide PO QD on days 1-21. Beginning in course 2, patients also receive AT-101 PO BID on days 1-3. Treatment repeats every 28 days for up to 11 courses (49-56 days for course 12 or last course of treatment) in the absence of disease progression or unacceptable toxicity.

Study Design Info

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Source: ClinicalTrials.gov